AR061066A1 - Coterapeutica para el tratamiento de epilepsia y trastornos relacionados - Google Patents

Coterapeutica para el tratamiento de epilepsia y trastornos relacionados

Info

Publication number
AR061066A1
AR061066A1 ARP070102201A ARP070102201A AR061066A1 AR 061066 A1 AR061066 A1 AR 061066A1 AR P070102201 A ARP070102201 A AR P070102201A AR P070102201 A ARP070102201 A AR P070102201A AR 061066 A1 AR061066 A1 AR 061066A1
Authority
AR
Argentina
Prior art keywords
group
hydrogen
epilepsy
effective amount
therapeutically effective
Prior art date
Application number
ARP070102201A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR061066A1 publication Critical patent/AR061066A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un método para tratar epilepsia o un trastorno relacionado, que comprende la administracion a un sujeto que lo necesita de una coterapéutica con una cantidad terapéuticamente efectiva de uno o varios agentes antiepilépticos o anticonvulsivantes y una cantidad terapéuticamente efectiva de un compuesto de la formula (1) en donde R1 está seleccionado del grupo que consiste en hidrogeno, halogeno, hidroxi, metoxi, trifluorometilo, nitro y ciano; X-Y está seleccionado del grupo que consiste en -S-CH-, -S-C(CH3)-, -O-CH-, -O-C(CH3)-, -N(CH3)-CH- y -CH=CH-CH-; A está seleccionado del grupo que consiste en -CH2- y -CH(CH3)-; R2 está seleccionado del grupo que consiste en hidrogeno y metilo; R3 y R4 están seleccionados cada uno, de modo independiente entre sí, del grupo que consiste en hidrogeno y alquilo C1-4; de modo alternativo, R3 y R4 se toman juntos con el átomo de nitrogeno al que están unidos para formar una estructura de anillo saturada, parcialmente insaturada o aromática de 5 a 7 miembros, que opcionalmente contiene uno a dos heteroátomos adicionales seleccionados, de modo independiente, del grupo que consiste en O, N y S; o una de sus sales farmacéuticamente aceptables.
ARP070102201A 2006-05-19 2007-05-21 Coterapeutica para el tratamiento de epilepsia y trastornos relacionados AR061066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80200106P 2006-05-19 2006-05-19

Publications (1)

Publication Number Publication Date
AR061066A1 true AR061066A1 (es) 2008-07-30

Family

ID=38510389

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102201A AR061066A1 (es) 2006-05-19 2007-05-21 Coterapeutica para el tratamiento de epilepsia y trastornos relacionados

Country Status (7)

Country Link
US (1) US20070293476A1 (es)
AR (1) AR061066A1 (es)
CL (1) CL2007001468A1 (es)
PE (1) PE20080234A1 (es)
TW (1) TW200812574A (es)
UY (1) UY30360A1 (es)
WO (1) WO2007137164A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
TWI397417B (zh) 2006-06-15 2013-06-01 Ucb Pharma Gmbh 具有協同抗驚厥功效之醫藥組成物
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10117891B2 (en) 2014-09-16 2018-11-06 India Globalization Capital, Inc. Cannabinoid composition for treating pain
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017218629A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
EP3769759B1 (en) 2018-03-20 2023-11-15 Eisai R&D Management Co., Ltd. Combination of an indanesulfamide derivative with perampanel for use in the treatment of epilepsy
WO2024054807A1 (en) * 2022-09-06 2024-03-14 Biohaven Therapeutics Ltd. Combination therapies including metal channel activators and tdp-43 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
WO1997019682A1 (en) * 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
EP1210118B1 (en) * 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
JP2007522248A (ja) * 2004-02-13 2007-08-09 ニューロモレキュラー・インコーポレイテッド てんかんおよび他のcns障害の処置のための、nmdaレセプターアンタゴニストと抗てんかん薬との組み合わせ
MY142329A (en) * 2004-08-24 2010-11-15 Janssen Pharmaceutica Nv Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis

Also Published As

Publication number Publication date
TW200812574A (en) 2008-03-16
US20070293476A1 (en) 2007-12-20
WO2007137164A2 (en) 2007-11-29
PE20080234A1 (es) 2008-04-25
UY30360A1 (es) 2007-08-31
CL2007001468A1 (es) 2008-04-04
WO2007137164A3 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
AR061066A1 (es) Coterapeutica para el tratamiento de epilepsia y trastornos relacionados
AR061067A1 (es) Coterapeutica para el tratamiento de epilepsia y trastornos relacionados
AR050530A1 (es) Derivados de heteroaril sulfamida benzo-fusionada utiles como agentes anticonvulsivos
AR059501A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
UY28833A1 (es) Piridonas sustituidas como inhibidores de poli (adp-ribosa)-polimerasa (parp).
AR109590A2 (es) Régimen posológico para inhibidores de comt
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
ECSP056020A (es) Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR068510A1 (es) Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central.
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
CL2009000815A1 (es) Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria.
ECSP067093A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
UY27304A1 (es) Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
AR068512A1 (es) Derivados de 4-aril-1h-piridin-2-onas disustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
PA8680701A1 (es) Derivados de oxindol
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
UY28150A1 (es) Agentes terapeuticos
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
ECSP045073A (es) Nuevos derivados de piperazina
AR072586A1 (es) Derivados de sulfamidas sustituidas, procesos para su preparacion y su uso para el tratamiento de trastornos del sistema nervioso y del metabolismo.
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal